Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.45 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422654 | 0.99 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL7885322 | 0.92 | ALDH1A1 (0.49) | L3MBTL3L3MBTL1HRH3MBTD1LMNA | |
| SCHEMBL422763 | 0.91 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1HRH3LMNAHPGD | |
| SCHEMBL422479 | 0.91 | HRH3 (0.51) | L3MBTL3L3MBTL1HRH3HPGDKDM4E | |
| SCHEMBL419957 | 0.90 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL419247 | 0.87 | HCAR3 (0.44) | L3MBTL3L3MBTL1HRH3HPGDKDM4E | |
| SCHEMBL419340 | 0.83 | KDM2B (0.48) | L3MBTL1HRH3HPGDKDM4EMEN1 | |
| SCHEMBL420929 | 0.82 | HRH3 (0.53) | L3MBTL3L3MBTL1HRH3HPGDKDM4E | |
| SCHEMBL7881443 | 0.82 | MEN1 (0.53) | L3MBTL3L3MBTL1HRH3LMNAHPGD | |
| SCHEMBL16297713 | 0.82 | MAPT (0.45) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2396327-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093425-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | L3MBTL3 1535/4885L3MBTL1 1600/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.